FDA drug chief signals possible exit as agency turmoil deepens

Richard Pazdur, the newly appointed chief of the FDA's drug division, has indicated a potential retirement just weeks into his role, contributing to the ongoing turmoil within the agency amid increasing political pressures.

This development raises concerns about the stability and leadership at the FDA, as finding a suitable replacement for Pazdur could prove difficult during a time of heightened scrutiny and internal conflict within the organization.

The situation reflects broader challenges faced by the FDA, including recent announcements of stricter vaccine approval protocols, which have drawn criticism and may further complicate the agency's ability to respond effectively to public health needs.